Add as a preferred source on GoogleMaxCyte Agrees to Acquire Akron Bio in $151.8 Million Deal
The proposed transaction includes $105 million in cash, shares valued at about $26.8 million and $20 million in guaranteed deferred payments.
MaxCyte, Inc. agreed to acquire Akron BioProducts LLC, also known as Akron Bio, for $151.8 million in a proposed transaction that remains subject to closing conditions.
MaxCyte entered the agreement Nov. 9 and announced it Nov. 10. The proposed consideration includes $105 million in cash, 20,639,733 MaxCyte shares valued at about $26.8 million and $20 million in guaranteed deferred payments.
MaxCyte's third-quarter 2026 revenue was $10.2 million, up 49% from a year earlier. Core revenue was $8.2 million. An earlier preliminary estimate of third-quarter core revenue put the figure at about $8.1 million.
The acquisition must satisfy closing conditions before it can be completed.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.